Geneva—Supportive care for patients with early, limited-stage small cell lung cancer (SCLC) using granulocyte colony-stimulating factor (G-CSF) along with concurrent chemoradiotherapy(CTRT) does not result in an increased risk for severe acute esophagitis, pneumonitis or toxicity-related death, according to a subanalysis of the phase 3 CONVERT trial.
“The use of G-CSF was not detrimental in PFS [progression-free survival] or OS [overall survival],” said lead investigator Fabio